ASC43F / Ascletis - LARVOL DELTA

A PHASE I, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ASC43F, A FIXED-DOSE COMBINATION ORAL TABLET OF ASC41, A THYROID HORMONE RECEPTOR BETA AGONIST AND ASC42, A FARNESOID X RECEPTOR AGONIST IN HEALTHY SUBJECTS (AASLD 2022) - "Results of this Phase I study demonstrated that ASC43F FDC showed good tolerability and safety profiles, and PK parameters of ASC41/ASC41A and ASC42 from ASC43F FDC were similar to those of ASC41/ASC41A and ASC42 as monotherapy."

Clinical • PK/PD data • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects (clinicaltrials.gov) - P1; N=8; Completed; Sponsor: Gannex Pharma Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects (clinicaltrials.gov) - P1; N=8; Recruiting; Sponsor: Gannex Pharma Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open